Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126801711 | 12680171 | 1 | I | 20160712 | 20160818 | 20160824 | 20160824 | EXP | GB-MHRA-MIDB-07580A9C-3DBB-4B54-8A3E-AD11312550CF | GB-009507513-1608GBR009862 | MERCK | 76.00 | YR | M | Y | 0.00000 | 20160824 | PH | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126801711 | 12680171 | 1 | PS | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 20 MG, QD | Y | U | 70017 | 20 | MG | TABLET | QD | ||||
| 126801711 | 12680171 | 2 | SS | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 25 MG, QD | Y | U | 0 | 25 | MG | TABLET | QD | ||||
| 126801711 | 12680171 | 3 | SS | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 50 MG, QD | Y | U | 0 | 50 | MG | TABLET | QD | ||||
| 126801711 | 12680171 | 4 | SS | NICORANDIL | NICORANDIL | 1 | Oral | 20 MG, BID | 0 | 20 | MG | BID | |||||||
| 126801711 | 12680171 | 5 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 75 MG, QD | 75 | MG | 0 | 75 | MG | QD | |||||
| 126801711 | 12680171 | 6 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 80 MG, HS (AT NIGHT) | 0 | 80 | MG | QD | |||||||
| 126801711 | 12680171 | 7 | C | DOUBLEBASE | ISOPROPYL MYRISTATEPARAFFIN | 1 | Topical | 0 | 1 | DF | |||||||||
| 126801711 | 12680171 | 8 | C | NITROGLYCERIN. | NITROGLYCERIN | 1 | Sublingual | 0 | 300 | UG | |||||||||
| 126801711 | 12680171 | 9 | C | ISOSORBIDE MONONITRATE. | ISOSORBIDE MONONITRATE | 1 | Oral | 60 MG, QAM (IN THE MORNING) | 0 | 60 | MG | PROLONGED-RELEASE TABLET | QD | ||||||
| 126801711 | 12680171 | 10 | C | TAMSULOSIN HYDROCHLORIDE. | TAMSULOSIN HYDROCHLORIDE | 1 | Oral | 0 | 400 | UG | QD | ||||||||
| 126801711 | 12680171 | 11 | C | BISOPROLOL | BISOPROLOL | 1 | Oral | 3.75 MG, QD | 0 | 3.75 | MG | QD | |||||||
| 126801711 | 12680171 | 12 | C | BISOPROLOL | BISOPROLOL | 1 | Oral | 5 MG, QAM (IN THE MORNING) | 0 | 5 | MG | QD | |||||||
| 126801711 | 12680171 | 13 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, QAM (IN THE MORNING) | 0 | 75 | MG | QD | |||||||
| 126801711 | 12680171 | 14 | C | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Oral | 1 G, Q4D | 0 | 1 | G | ||||||||
| 126801711 | 12680171 | 15 | C | QUININE SULFATE. | QUININE SULFATE | 1 | Oral | 200 MG, QD | 0 | 200 | MG | QD | |||||||
| 126801711 | 12680171 | 16 | C | TRAMADOL HYDROCHLORIDE. | TRAMADOL HYDROCHLORIDE | 1 | 50MG-1G 4 HOURLY | 0 | |||||||||||
| 126801711 | 12680171 | 17 | C | WARFARIN | WARFARIN | 1 | 3 MG, UNK | 0 | 3 | MG | |||||||||
| 126801711 | 12680171 | 18 | C | WARFARIN | WARFARIN | 1 | 5 MG, UNK | 0 | 5 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126801711 | 12680171 | 17 | Anticoagulant therapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126801711 | 12680171 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126801711 | 12680171 | Acute kidney injury | |
| 126801711 | 12680171 | Infected skin ulcer | |
| 126801711 | 12680171 | Pain | |
| 126801711 | 12680171 | Skin discolouration | |
| 126801711 | 12680171 | Skin exfoliation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126801711 | 12680171 | 5 | 20160713 | 0 |